DC
AQST icon

Diametric Capital’s Aquestive Therapeutics AQST Stock Holding History

Diametric Capital’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-335,443
Closed -$1.39M – 490
2026
Q1 		$1.39M Buy
335,443
+206,967
+161% +$840K 0.36% 61
2025
Q4 		$830K Sell
128,476
-10,596
-8% -$66K 0.22% 118
2025
Q3 		$777K Sell
139,072
-26,301
-16% -$114K 0.29% 80
2025
Q2 		$547K Buy
+165,373
New +$474K 0.29% 97
2025
Q1 		– Sell
-35,295
Closed -$126K – 227
2024
Q4 		$126K Sell
35,295
-10,035
-22% -$46.3K 0.08% 263
2024
Q3 		$226K Sell
45,330
-197,382
-81% -$768K 0.11% 281
2024
Q2 		$631K Buy
242,712
+174,624
+256% +$583K 0.34% 74
2024
Q1 		$290K Buy
+68,088
New +$227K 0.16% 168

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Diametric Capital's AQST Position: Q2 2026 in Review

Diametric Capital sold out of Aquestive Therapeutics (AQST) in Q2 2026, closing a stake of 335,443 shares — an estimated $1.39M sold.

Diametric Capital first reported a position in AQST in Q1 2024 and held it in 8 quarters. The position peaked at $1.39M in Q1 2026. 185 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Diametric Capital reported no remaining Aquestive Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Diametric Capital sold 335,443 Aquestive Therapeutics shares in Q2 2026, an estimated $1.39M.
  • Diametric Capital first reported a position in Aquestive Therapeutics in Q1 2024 and held it in 8 quarters.
  • Diametric Capital's Aquestive Therapeutics position peaked at $1.39M in Q1 2026.
  • 185 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Diametric Capital's 13F filing for Q2 2026, filed 14 Aug 2026.